MAPT and Alzheimer disease: Taken together, these data suggest that NDP treatment and MCR stimulation in late phase of AD progression is not able to decrease the Aβ burden in severe mouse models of AD, such as 5XFAD and 3xTg mice, but is able to reduce tau phosphorylation that is known to better correlate with cognitive abilities (38).